Aripiprazole Tablet
Product Images NDC 68071-3850

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68071-3850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3850 3)

Aripiprazole 10 mg tablets label from NuCare Pharmaceuticals, Inc., packaging containing 30 tablets. The label includes standard prescription drug information such as NDC 68071-3850-3, manufacturer's lot and expiration details, a product number, and usage warnings. Storage instructions specify a controlled temperature of 68-77°F.*

FDA Label Image

Aripiprazolefigure1 (Aripiprazolefigure1)

A pharmacokinetic chart showing Aripiprazole fold change with 90% confidence intervals. The chart compares AUC and Cmax values for Aripiprazole when administered with various CYP3A4 and CYP2D6 inhibitors, an inducer, gastric acid blockers, and other agents relative to a reference without interacting drugs. The x-axis displays change relative to reference (0.5 to 3.0 scale), and the y-axis lists interacting drugs and pharmacokinetic parameters measured.*

FDA Label Image

Aripiprazolefigure2 (Aripiprazolefigure2)

A pharmacokinetic chart showing the effect of various drugs on dehydro-aripiprazole levels. It plots fold change and 90% confidence intervals for AUC and Cmax of aripiprazole with co-administration of CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and other drugs valproate, lithium, and lorazepam, relative to a reference without interacting drugs.*

FDA Label Image

Aripiprazolefigure3 (Aripiprazolefigure3)

A horizontal bar chart titled 'Effect of Aripiprazole on Other Drugs' illustrating fold change and 90% confidence intervals for various drugs/metabolites measured by pharmacokinetic parameters such as AUC and Cmax or pharmacodynamic INR. Drugs include dextromethorphan, warfarin (S- and R-isomers), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine and its metabolite, and escitalopram. The x-axis shows change relative to a reference without interacting drug, ranging from 0.5 to 3.0.*

FDA Label Image

Aripiprazolefigure4 (Aripiprazolefigure4)

A pharmacokinetic chart showing Aripiprazole fold change with 90% confidence intervals across various special populations. The x-axis represents the change relative to reference, and the y-axis lists populations including CYP2D6 metabolizer status, gender, age groups, hepatic and renal impairment, with pharmacokinetic parameters AUC and Cmax compared.*

FDA Label Image

Aripiprazolefigure5 (Aripiprazolefigure5)

A pharmacokinetic (PK) chart depicting dehydro-aripiprazole fold change with 90% confidence intervals for various factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis shows change relative to reference, while the y-axis lists the factors compared with reference groups.*

FDA Label Image

Aripiprazolefigure6 (Aripiprazolefigure6)

A Kaplan-Meier curve chart comparing the proportion of relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk for each group at multiple time points.*

FDA Label Image

Aripiprazolefigure7 (Aripiprazolefigure7)

A line chart comparing the proportion with relapse over 182 days from randomization for Aripiprazole versus placebo. The x-axis represents days from randomization and the y-axis shows proportion with relapse. Two lines indicate relapse proportions for Aripiprazole and placebo groups, with subject counts at risk noted below the x-axis for both groups.*

FDA Label Image

Aripiprazolefigure8 (Aripiprazolefigure8)

This is a Kaplan-Meier survival curve showing the proportion of subjects with relapse over 364 days from randomization, comparing Aripiprazole tablets (10 mg) to placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes the number of subjects at risk at various time points for both groups.*

FDA Label Image

Aripiprazolefigure9 (Aripiprazolefigure9)

A line graph showing the change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: Abilify Low, Abilify High, and Placebo, with YGTSS score change plotted on the vertical axis and weeks of treatment on the horizontal axis.*

FDA Label Image

Aripiprazolestructure (Aripiprazolestructure)

Chemical structure of aripiprazole showing its molecular framework with two chlorine atoms on the phenyl ring, a piperazine ring, and the quinolinone moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.